Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

Kantarjian, Hagop; L. Sawyers, Charles; Hochhaus, Andreas; Guilhot, François; A. Schiffer, Charles; Gambacorti‐Passerini, Carlo; Niederwieser, Dietger; Resta, Debra; Capdeville, Renaud; Zoellner, Ulrike; Talpaz, Moshe; Druker, Brian

doi:10.1056/nejmoa011573

Public

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

Published in New England Journal of Medicine • Feb 28, 2002

Authors:

Hagop Kantarjian

Charles L. Sawyers

Andreas Hochhaus

Abstract

BACKGROUND: Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase. METHODS: A total of 532 patients with late--chronic-phase CML in whom previous therapy wit...

Subject

Medicine

Imatinib mesylate

Chronic myelogenous leukemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!